Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.
Graille-Avy L, Boutiere C, Rigollet C, Perriguey M, Rico A, Demortiere S, Durozard P, Hilezian F, Vely F, Bertault-Peres P, Pelletier J, Maarouf A, Audoin B. Graille-Avy L, et al. Among authors: maarouf a. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200231. doi: 10.1212/NXI.0000000000200231. Epub 2024 Apr 16. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38626360 Free article.
Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
Demortiere S, Joubert B, Benaiteau M, Hilezian F, Boutiere C, Rico A, Stolowy N, Dubois V, Audoin B, Maarouf A, Pelletier J. Demortiere S, et al. Among authors: maarouf a. Neurology. 2024 Apr 23;102(8):e209284. doi: 10.1212/WNL.0000000000209284. Epub 2024 Mar 25. Neurology. 2024. PMID: 38527243 No abstract available.
Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase.
Tishova Y, Kalinchenko S, Mskhalaya G, Hackett G, Livingston M, König C, Strange R, Zitzmann M, Mann A, Maarouf A, Ramachandran S. Tishova Y, et al. Among authors: maarouf a. Diabetes Obes Metab. 2024 Jun;26(6):2147-2157. doi: 10.1111/dom.15520. Epub 2024 Mar 3. Diabetes Obes Metab. 2024. PMID: 38433502 Clinical Trial.
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Venet M, Lepine A, Maarouf A, Biotti D, Boutiere C, Casez O, Cohen M, Durozard P, Demortière S, Giorgi L, Maillart E, Mathey G, Mazzola L, Rico A, Camdessanche JP, Deiva K, Pelletier J, Audoin B. Venet M, et al. Among authors: maarouf a. Mult Scler. 2024 Feb;30(2):261-265. doi: 10.1177/13524585231223069. Epub 2024 Jan 2. Mult Scler. 2024. PMID: 38166437
Comparison of patients with biopsy positive and negative primary angiitis of the central nervous system.
Nehme A, Arquizan C, Régent A, Isabel C, Dequatre N, Guillon B, Capron J, Detante O, Lanthier S, Poppe AY, Boulouis G, Godard S, Terrier B, Pagnoux C, Aouba A, Touzé E, de Boysson H; Cohort of Patients with PACNS study group. Nehme A, et al. Rheumatology (Oxford). 2023 Oct 6:kead542. doi: 10.1093/rheumatology/kead542. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37802919
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
Claverie R, Perriguey M, Rico A, Boutiere C, Demortiere S, Durozard P, Hilezian F, Dubrou C, Vely F, Pelletier J, Audoin B, Maarouf A. Claverie R, et al. Among authors: maarouf a. Neurol Neuroimmunol Neuroinflamm. 2023 Aug 21;10(5):e200152. doi: 10.1212/NXI.0000000000200152. Print 2023 Sep. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37604695 Free PMC article.
167 results